Create a Report
Please provide report title
Please provide location
Please provide details
Get alerts and updates for your case! Your contact information is not shown on the website.
This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.
Please provide email or phone
Please provide email or phone

We do not show your email or contact info

Please accept our Terms & Conditions
Add photos or video
We recommend photos and videos to help explain your report
Add Photo/Video
Email or SMS copy of report
Enter below to get emailed a copy of your report, or sms a link to your report
Please provide email or phone
Please provide email or phone
Please accept our Terms & Conditions
Thank you for your report!


IMPORTANT - Your report is queued
It may take up to 12 hours to process your report.


Email us at support@safelyhq.com if you have questions.

Report by
Loading...
Please provide location
Please provide location
Please provide report title
Please provide details
Please accept our Terms & Conditions
Get alerts and updates for your case! Your contact information is not shown on the website.

This information is not shown on the website. We can notify you of updates, and may contact you for more information to help resolve or follow up on your issue.

or
Please provide email or phone
Thank you for your report!

IMPORTANT - YOUR REPORT IS QUEUED - IT MAY TAKE UP TO 12 HOURS FOR YOUR REPORT TO SHOW ON OUR HOME PAGE (IF NOT OPTED AS PRIVATE)

Visit our learn pages for more helpful information or, email us: support@safelyhq.com

Goodbye! and best wishes in your recovery

Drugs

Updated: January 9, 2023 11:00 PM
Spectrum Laboratory Products, Inc. is voluntarily recalling three lots of Epinephrine (L-Adrenaline) USP, a bulk active pharmaceutical ingredient (API) used to manufacture or compound prescription products, to the user level. Customer complaints have found the product to be discolored. Product was distributed directly from Spectrum facilities nationwide... See More in the USA and to Canada.

Risk Statement: Epinephrine is a critical medication used during life-threatening conditions which can affect any age and any person. The use of a finished dose product manufactured or compounded with this recalled product could result in less-effective product, and incomplete treatment of life-threatening conditions including, low blood pressure, heart failure, anaphylaxis, irregular heartbeat, and heart attack. Treatment with a less-effective product, essentially underdosing epinephrine, could result in death. Spectrum Laboratory Products, Inc. has not received any reports of adverse events related to this recall.

Epinephrine (L-Adrenaline) USP bulk API Powder, is used in manufacturing and compounding of finished dose epinephrine prescription products which can be used to treat a variety of medical conditions including anaphylaxis and other severe immediate hypersensitivity reactions, asthma, bronchospasm, airway edema, nasal congestion, dilation during intraocular surgery, vasoconstrictor with local anesthetics, hypotension or shock, heart failure, bradycardia or atrioventricular block, and sudden cardiac arrest.

The Epinephrine (L-Adrenaline) USP bulk API Powder is packaged in amber glass bottles enclosed in a vacuum sealed pouch. NDC’s, Package sizes, lot numbers and expiration dates can be found in the table below. The affected Epinephrine, USP product can be identified by Spectrum catalog number EP130.

Product: Epinephrine, USP (Product code EP130)
NDC: 49452-2740-2
Package Size: 1 KG
Lot # 1KG0865
Exp Date: 31-Mar-2023

Product: Epinephrine, USP (Product code EP130)
NDC: 49452-2740-1
Package Size:100 GM
Lot # 2KL0353 / 2KF0151
Exp Date: 30-Sep-2023 / 31-Mar-2023

Product: Epinephrine, USP (Product code EP130)
NDC: 49452-2740-4
Package Size: 1 GM
Lot # 2KL0353 / 2KF0151
Exp Date: 30-Sep-2023 / 31-Mar-2023

Product: Epinephrine, USP (Product code EP130)
NDC: 49452-2740-3
Package Size: 25 GM
Lot # 2KL0353 / 2KF0151
Exp Date: 30-Sep-2023 / 31-Mar-2023

Product: Epinephrine, USP (Product code EP130)
NDC: 49452-2740-5
Package Size: 5 GM
Lot # 2KL0353 / 2KF0151
Exp Date: 30-Sep-2023 / 31-Mar-2023

Consumers, distributors, or retail pharmacies that have Epinephrine, USP catalog number EP130, which is being recalled, should stop use immediately and return to place of purchase.

In case you experienced harm from this product, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance.

Company name: Spectrum Laboratory Products Inc.
Brand name: Spectrum
Product recalled: Epinephrine bulk API
Reason of the recall: Product discoloration
FDA Recall date: January 09, 2023

Source: fda.gov
See Less
497


Pfizer company, is voluntarily recalling one lot of Vancomycin Hydrochloride Injection, USP, 1.5 g/vial Single Dose Fliptop Vial, lot 33045BA, to the user level due to two visible glass particulates observed in a single vial. The product was distributed nationwide to wholesalers/hospitals/ institutions in the United States... See More and Puerto Rico from June 23, 2022 through September 19, 2022.

If administered intravenously, patients may experience adverse events such as local irritation or swelling, vasculitis/ phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism. If administered orally or via a nasogastric tube, there may be the potential for gastrointestinal trauma. The risk is reduced by the possibility of detection, as the label contains a statement directing the healthcare professional to visually inspect the product for particulate matter and discoloration prior to administration.

To date, Pfizer has not received reports of any adverse events related to this recall. Vancomycin Hydrochloride is an antibiotic indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant staphylococci. Vancomycin Hydrochloride is effective in the treatment of staphylococcal endocarditis, septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. It is used in penicillin-allergic patients, and also for patients who cannot receive or who have failed to respond to other antimicrobials, including penicillin or cephalosporin agents, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobials.

The NDC, Lot Number, Expiration Date, and Configuration details for Vancomycin HCl for injection, USP are indicated below.

Product: Vancomycin Injection, USP, Single-Dose Fliptop Vial
NDC: Vial: 0409-3515-11 Carton: 049-3515-01
Lot Number: 33045BA
Expiration Date: 1SEP2023
Presentation: 1.5 g/Vial
Configuration/Count: 10 units/carton, 10 cartons/case

Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. Pfizer has notified direct consignees by letter to arrange for return of any recalled product.

Wholesalers, hospitals, institutions, and doctors with an existing inventory of the lot, which is being recalled, should discontinue use, stop distribution, and quarantine immediately. If you have further distributed the recalled product, please notify your accounts and/or any additional locations which may have received the recalled product.

In case you experienced harm from these products, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance. If symptoms persist, seek medical care.

Company name: Hospira, Inc.
Brand name: Hospira, Inc.
Product recalled: Vancomycin Injection
Reason of the recall: Presence of Visible Glass Particulates
FDA Recall date: December 27, 2022

Source: fda.gov
See Less
497


Durham, North Carolina, Accord Healthcare, Inc. is voluntarily recalling a single lot of Daptomycin for Injection 500 mg/vial, and Daptomycin for Injection 350 mg/vial product contained in cartons imprinted with lot # R2200232 Exp: 01/2025 to the consumer/user level. This product is being recalled because Accord received... See More a product complaint report from a hospital pharmacy that vials labeled as “Daptomycin for Injection 500 mg/vial” were found in cartons labeled as “Daptomycin for Injection 350 mg/vial”. These products were distributed to wholesale nationwide in the USA.

The lot and expiration date printed on the outer carton and inner vial are the same and correspond to “Daptomycin for Injection 500 mg/vial.” Accordingly, Accord is voluntarily recalling all of lot #R2200232, Daptomycin for Injection 500 mg/vial, which may be in outer cartons that read “Daptomycin for Injection 500 mg/vial” OR “Daptomycin for Injection 350 mg/vial.” 

- Affected products:

Product: Daptomycin for Injection 500 mg/vial
NDC: 16729-435-05
Lot number/Expiration Date: R2200232, 01/2025

Product: Daptomycin for Injection 350 mg/vial
NDC: 16729-434-05
Lot number/Expiration Date: R2200232, 01/2025

Company name: Accord Healthcare, Inc
Brand name: Accord
Product recalled: Daptomycin for Injection
Reason of the recall: Mislabeling
FDA Recall date: December 27, 2022

Risk Statement: Administration of Daptomycin 500 mg/vial, to the population most at risk which are children or patients with renal impairment, there is a reasonable probability that the likelihood of the labeled warnings can potentially be increased if a higher than the intended dose is used which could lead to serious adverse health consequences. If these reactions occur, they may require medical treatment such as hemodialysis and systemic glucocorticoids. To date, Accord has not received any reports of adverse events related to this recall.

The product is used for the treatment of adult and pediatric patients (1 to 17 years of age) with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureaus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only).

The lot number, NDC number and expiration date of affected Daptomycin 500 mg/vial and Daptomycin 350 mg/vial product is shown below:

Product: Daptomycin for Injection 500 mg/vial
NDC: 16729-435-05
Lot number/Expiration Date: R2200232, 01/2025

Product: Daptomycin for Injection 350 mg/vial
NDC: 16729-434-05
Lot number/Expiration Date: R2200232, 01/2025

In case you experienced harm from these products, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance. If symptoms persist, seek medical care.

Source: fda.gov
See Less
497


Lupin Pharmaceuticals Inc. is voluntarily recalling four (4) lots of Quinapril Tablets to the patient (consumer/user) level due to the presence of a nitrosamine impurity, N-Nitroso-Quinapril, observed in recent testing above the Acceptable Daily Intake (ADI) level. To date, Lupin has received no reports of illness that... See More appear to relate to this issue. Lupin discontinued the marketing of Quinapril tablets in September 2022. It was distributed nationwide in the US to wholesalers, drug chains, mail-order pharmacies, and supermarkets.

Nitrosamines are common in water and foods, including cured and grilled meats, dairy products, and vegetables. Everyone is exposed to some level of nitrosamines. These impurities may increase the risk of cancer if people are exposed to them above acceptable levels over long periods of time. Quinapril tablet USP is an angiotensin-converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

Quinapril Tablets USP 20mg, and 40mg is packaged in 90 count bottles. The recalled lots are included in the table below:

Product: Quinapril Tablets USP, 20mg
Lot No: G102929
Expiry: 04/2023
NDC: 68180-558-09 (90’s)
UPC: 368180558095
Distribution Dates: 03/15/2021 – 09/01/2022

Product: Quinapril Tablets USP, 40mg
Lot No: G100534, G203071, G100533
Expiry: 12/2022, 12/2022, 03/2024
NDC: 68180-554-09 (90’s)
UPC: 368180554097
Distribution Dates: 03/15/2021 – 09/01/2022

Lupin Pharmaceuticals Inc. is notifying its wholesalers, distributors, drug chains, mail order pharmacies and supermarkets by phone and through recall notification and is arranging for the return of all the recalled product lots.

Patients taking, Quinapril Tablets USP, 20mg, and 40mg are advised to continue taking their medication and contact their pharmacist, physician, or medical provider for advice regarding an alternative treatment.

Wholesalers, distributors and retailers that have Quinapril Tablets USP, 20mg, and 40mg that are being recalled should discontinue distribution of the recalled product lots immediately.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Company name: Lupin Pharmaceuticals Inc.
Brand name: Lupin
Product recalled: Quinapril 20 and 40 mg tablets
Reason of the recall: Presence of nitrosamine impurity, N-Nitroso-Quinapril
FDA Recall date: December 21, 2022

Source: fda.gov
See Less
497


LV
l.....e
These thieves just sent me one of those feathered pens (dolin youpin 1502 Worlds Map Series). I reported it to my bank and now I am reporting it to the Las Vegas Police which I recommend everybody does. The bastards have a website to sell stuff, like ink for this pen , but Ill buy my ink from Office Depot. There has to be a way to shut these bastards down. Let's do it together.
Reply 2 weeks ago
Heavy marijuana use in the apartment beneath me See Less
1.2K


RK
anonymous10021
Call the police to report it then,
Reply 2 weeks ago
GlaxoSmithKline Consumer Healthcare ULC is recalling one lot of TUMS Peppermint Regular Strength tablets after some tablets were found to contain fragments of fibreglass and other material, including paper and aluminum foil. The product is sold in a package of three rolls containing 12 tablets each, and... See More was distributed across Canada starting on October 25, 2022.

The recalled product is:
- TUMS Peppermint Regular Strength (500mg) tablets, packages of three rolls of 12 tablets, NPN: 01970240, Lot: HA7H, Expiry: August 2027

Company name: GlaxoSmithKline Consumer Healthcare ULC
Product recalled: TUMS Peppermint Regular Strength (500mg) tablets, packages of three rolls of 12 tablets
Reason of the recall: Due to contamination fragments of fibreglass and other material
CFIA Recall date: November 30, 2022

TUMS is an antacid indicated for adult use to relieve indigestion and heartburn caused by too much acid in the stomach. If consumed, the fragments should pass through most people's digestive systems with no concern; however, elderly people and people who have narrow areas in their intestines because of disease or surgery may be at risk of injury.

Stop using the recalled product. Follow municipal or regional guidelines on how to dispose of chemicals and other hazardous waste; or Return the product to your local pharmacy for proper disposal.

In case you experience harm from this product, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance. If symptoms persist, seek medical care.

Source: recalls-rappels.canada.ca
See Less
64


Medicine for OAB Trospium Chloride 20mg - first 3 pills worked fine 4th pill not the same was like a strong diet pill kept me up all night with heart beating too fast the following days heart was still beating faster than normal - I reported the... See More problem to the pharmacy and my Doctor and discontinued the pill. It was unstable medicine did not make any sense - I was going to the bathrrom too many times at night for a long period of time | Symptoms: Diarrhea, Other See Less
1.7K


Exela Pharma Sciences, LLC, (Exela) is expanding their recall, adding fourteen (14) lots to the ongoing voluntary recall of forty-nine (49) lots of Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial, 20-count carton. A total of 63 lots are now being recalled to the consumer level.... See More All the recalled lots are listed in the table below, with the additional fourteen (14) lots shown in BOLD and RED. The additional lots were distributed October 26, 2021 through April 25, 2022. Product was distributed nationwide to wholesalers, distributors, and other customers between October 26, 2021 and August 10, 2022. There have been no reports of sterility failures to date with any of the sixty-three (63) lots.

Risk Statement: The product poses a potential safety concern with vial breakage and flying glass when pressurized while preparing the product for administration. There is a potential of flying glass injuring skin, eye and/or other parts which could result in either temporary or permanent injury. Within the sixty-three (63) total recalled lots (which includes more than 2.7 million vials), Exela has received five (5) reports of flying glass injuring skin, eye and/or other parts. There have been no complaints of vial breakage or injuries related to the additional fourteen (14) lots.

Exela did not recall the additional fourteen (14) lots previously because they did not appear to be impacted. During the latest inspection of Exela’s retain product from the fourteen (14) lots, one (1) vial showed breakage. There have been no field reports of personal injury to date across all the sixty-three (63) lots since the recall process started. However, out of an abundance of caution, Exela is adding the 14 lots to the on-going recall. The product is used for treatment of metabolic acidosis and is packaged in a 50 mL glass vial, 20 vials per carton. The vials are labeled with Exela brand (Carton NDC: 51754-5001-5; Vial NDC: 51754-5001-1, Figure 1) and Civica brand (Carton NDC: 72572-740-20; Vial NDC: 72572-740-1, Figure 2). The affected Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL lots (covering both Exela and Civica brands) include the following lot numbers and expiration dates:

- Brand : Exela . Lot : P0001178 . Expire Date: 05/2023.
- Brand : Exela . Lot : P0001298 . Expire Date: 08/2023.
- Brand : Exela . Lot : P0001301 . Expire Date: 08/2023.
- Brand : Exela . Lot : P0001313 . Expire Date: 08/2023.
- Brand : Exela . Lot : P0001314 . Expire Date: 08/2023.
- Brand : Exela . Lot : P0001317 . Expire Date: 08/2023.
- Brand : Exela . Lot : P0001330 . Expire Date: 09/2023.
- Brand : Exela . Lot : P0001370 . Expire Date: 10/2023.
- Brand : Exela . Lot : P0001371 . Expire Date: 10/2023.
- Brand : Exela . Lot : P0001372 . Expire Date: 10/2023.
- Brand : Exela . Lot : P0001433 . Expire Date: 11/2023.
- Brand : Exela . Lot : P0001434 . Expire Date: 11/2023.
- Brand : Exela . Lot : P0001442 . Expire Date: 11/2023.
- Brand : Exela . Lot : P0001443 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001464 . Expire Date: 09/2023.
- Brand : Exela . Lot : P0001467 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001468 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001469 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001470 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001472 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001486 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001495 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001505 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001506 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001509 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001510 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001511 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001512 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001532 . Expire Date: 12/2023.
- Brand : Exela . Lot : P0001560 . Expire Date: 01/2024.
- Brand : Exela . Lot : P0001561 . Expire Date: 01/2024.
- Brand : Exela . Lot : P0001562 . Expire Date: 01/2024.
- Brand : Exela . Lot : P0001564 . Expire Date: 01/2024.
- Brand : Exela . Lot : P0001566 . Expire Date: 01/2024.
- Brand : Exela . Lot : P0001567 . Expire Date: 01/2024.
- Brand : Exela . Lot : P0001568 . Expire Date: 01/2024.
- Brand : Exela . Lot : P0001571 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001572 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001573 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001574 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001578 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001579 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001580 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001583 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001586 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001587 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001588 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001593 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001594 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001610 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001618 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001619 . Expire Date: 02/2024.
- Brand : Exela . Lot : P0001644 . Expire Date: 03/2024.
- Brand : Exela . Lot : P0001645 . Expire Date: 03/2024.
- Brand : Exela . Lot : P0001646 . Expire Date: 03/2024.
- Brand : Exela . Lot : P0001654 . Expire Date: 02/2024.
- Brand : Civica . Lot : P0001490 . Expire Date: 12/2023.
- Brand : Civica . Lot : P0001497 . Expire Date: 12/2023.
- Brand : Civica . Lot : P0001600 . Expire Date: 02/2024.
- Brand : Civica . Lot : P0001663 . Expire Date: 03/2024.

The Exela product (Carton NDC: 51754-5001-5; Vial NDC: 51754-5001-1) can be identified by the NDC numbers, and by the yellow flip-top safety cap on the 50 mL vial. The carton bears a purple stripe containing concentration information and the manufacturer name “Exela Pharma Sciences” in the lower right-hand corner. The vial label bears a purple stripe containing concentration information with the name “Exela Pharma Sciences” on the back.

The Civica Product (Carton NDC: 72572-740-20; Vial NDC: 72572-740-1) can be identified by the NDC numbers, by the yellow flip-top safety cap on the 50 mL vial, and by the carton which bears a green stripe containing concentration information and the manufacturer name “Civica” in the lower right-hand corner. The vial label bears a green stripe containing concentration information with the name “Civica” on the back.

All the above-listed lots are supplied in 20 count cartons only. This recall is not expected to cause drug shortage.

Customers that have product which is being recalled should discontinue use, segregate the recalled product, submit a recall stock response form to Exela (even if there is no product to return).

In case you experienced harm from this product, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance.

Company name: Exela Pharma Sciences, LLC
Brand name: Exela
Product recalled: Sodium Bicarbonate Injection, USP, 8.4%, 50 mEq/50 mL vial
Reason of the recall: Vial Breakage
FDA Recall date: November 29, 2022

Source: fda.gov
See Less
497


Mason Vitamins Inc. has issued a nationwide voluntary recall of the specific lot of Healthy Sense Daily Multiple with Iron and People’s Choice Women's Daily Vitamins with Iron due to Vitamin A, Vitamin B12, Vitamin C, Vitamin E and Pantothenic Acid amounts being lower than the declared... See More amount on the label which was determined during an FDA inspection. The products were sold nationwide at Bargain Barn, 99 Cents Only, Fruth Pharmacy, Joe V’s Smart Shop, Rose’s Discount Stores, Rex Discount Pharmacy, Star Discount Pharmacy, Propst Discount Pharmacy, Dollar Tree and limited distributors. To date, no illnesses related to these products have been reported.

Product Name: Healthy Sense Daily Multiple with Iron, Size: 20 tablets, UPC Code: 311845353238, Lot/Expiration Date: 25807G / 09/2024
Product Name: People’s Choice Women’s Daily Vitamins with Iron, Size: 30 tablets, UPC Code: 311845486882, Lot/Expiration Date: 25807G / 09/2024; A25807G / 09/2024; B25807G / 09/2024;C25807G / 09/2024; D25807G / 09/2024

No other People’s Choice and Healthy Sense products are affected by this recall. If customers have product affected by this voluntary recall, they should discard it immediately.

In case you experienced harm from these products, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance.

Company name: Mason Vitamins Inc.
Brand name: Healthy Sense and People’s Choice
Product recalled: Daily multi vitamin with Iron and Women’s daily vitamin with iron
Reason of the recall: Due to Vitamin 1, B12, C, E and Pantothenic Acid being lower than declared
FDA Recall date: November 17, 2022

Source: fda.gov
See Less
497


Mylan Institutional LLC, a Viatris company, is voluntarily recalling lot AJ21002, exp 3/2024, of Octreotide Acetate Injection, 500 mcg/mL, packaged in a carton of ten 1mL syringes. This lot is being recalled at the user (hospital/pharmacy) level due to a product complaint of the presence of glass... See More particles in a syringe. This lot was manufactured by Italfarmaco SpA, Italy and was distributed by Mylan Institutional LLC in the US between January 11 and June 21, 2022. To date, no reports of adverse reactions associated with this lot have been received.

The recalled lot is as follows:

NDC #: 67457-246-00 (Syringe); 67457-246-01 (Carton), Name and Strength: Octreotide Acetate Injection 500 mcg/mL, Size: 10 X 1 mL Single dose unit-of-use Syringe. Lot#: AJ21002, Expiry: March 2024

Intravenous administration of a solution containing particulate matter, such as a glass, could lead to events including, but not limited to, local irritation or swelling, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism. Although the intravenous administration of a solution containing particulate matter may pose potential risk of serious adverse events, the probability of exposure from this incident and subsequent risk is low.

Octreotide Acetate Injection is indicated to reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. It is also indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease and for the treatment of the profuse watery diarrhea associated with vasoactive intestinal peptide (VIP)-secreting tumors.

The company has initiated the recall of lot AJ21002 and notified its distributors by letter/phone and is arranging for return of all recalled products. Following are actions for wholesalers and retailers/users (hospitals/pharmacies):

Wholesalers: Immediately examine your inventory, quarantine and discontinue distribution of this lot.

Retailers/Users (Hospitals/Pharmacies): Immediately examine your inventory, quarantine and discontinue distribution of this lot.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

In case you experienced harm from this product, it is important to report it. It can help to detect & resolve issues and prevent others from being harmed, and it enables better surveillance.

Company name: Mylan Institutional LLC, a Viatris company
Brand name: Mylan Institutional LLC
Product recalled: Octreotide Acetate Injection, 500 mcg/mL
Reason of the recall: Due to glass particulates
FDA Recall date: October 25, 2022

Source: fda.gov
See Less
497


Last 30 days